查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951925

消化器官系统药物市场分析及预测（至2035年）：类型、产品、应用、最终用户、技术、剂型、成分、製程及模式

Gastrointestinal Drugs Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Form, Component, Process, Mode
出版日期: | 出版商: Global Insight Services | 英文 362 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，消化器官系统药物市场规模将从2024年的612亿美元成长至1,014亿美元，复合年增长率约为5.3%。消化器官系统药物市场涵盖用于治疗消化器官系统疾病的药物，例如酸相关疾病、便秘和发炎性肠道疾病。推动市场成长的因素包括胃肠道疾病盛行率的上升、人口老化以及人们对肠道健康的日益关注。药物递送系统和生物製药的创新正在提高治疗效果和患者依从性，而新兴市场则提供了成长机会。该市场竞争激烈，重点在于研发和策略合作，以满足尚未满足的市场需求。

受胃肠道疾病发病率上升和药物製剂技术进步的推动，消化器官系统药物市场正经历强劲成长。酸中和剂，尤其是质子帮浦阻断剂，因其在治疗酸相关疾病方面的有效性而表现突出。止吐药，特别是5-羟色胺受体拮抗剂，因其在控制噁心和呕吐方面的有效性而成为表现第二好的细分市场。生物製药因其能够为发炎性肠道疾病等慢性疾病提供标靶治疗日益受到重视。非处方药市场需求不断成长，反映出消费者对更便利治疗方案的偏好。处方药仍然占据主导地位，创新治疗方法正在改善患者的治疗效果。新型药物递送系统（例如缓释製剂）的开发正在提高治疗效果和患者依从性。策略联盟和研发投资正在加速先进消化器官系统药物的上市，进一步提升市场潜力。对个人化医疗的关注有望改变治疗模式，并带来巨大的成长机会。

市场区隔
类型 制酸剂、泻药、止泻药、抗溃疡药、止吐药、生物製药製剂、质子帮浦阻断剂、H2受体阻断剂
产品 锭剂、胶囊、粉末、液体、注射、凝胶剂、栓剂、乳膏剂
适应症 大肠激躁症、胃食道逆流、消化性溃疡、克隆氏症、溃疡性大肠炎、乳糜泻、憩室炎、功能性消化不良
最终用户 医院、诊所、居家医疗机构、专科护理中心、研究机构、诊断中心、学术机构、製药公司
科技 生物技术、合成、奈米技术、重组DNA、高通量筛检
形式 固体、液态、固体
成分 活性药物成分、添加剂、防腐剂、色素、粘合剂、润滑剂、包衣剂
流程 配方、生产、包装、品管、分销
形式 处方药和非处方药

消化器官系统药物市场产品组合丰富多样，现有企业透过策略定价和创新产品推出维持显着的市场份额。新参与企业取得了显着进展，尤其是在新型製剂和标靶治疗，满足了尚未被满足的医疗需求。竞争格局瞬息万变，各公司正利用先进的药物递送系统来提高疗效和病患依从性。定价策略竞争激烈，反映了可及性和盈利之间的平衡。在新兴市场，由于医疗保健意识的提高和对有效胃肠道治疗的需求，市场渗透率正在不断增长。竞争基准分析显示，少数几家主要企业占据主导地位，而规模较小的企业也透过提供利基产品来扩大市场份额。监管影响显着，严格的核准流程决定企业的市场准入和扩张。食品药物管理局) 和欧洲药品管理局 (EMA) 在製定影响药物生命週期管理的标准方面发挥关键作用。市场分析表明，在生物製药技术的进步推动下，个人化医疗正在成为一种趋势。数据分析和真实世界数据 (RWE) 越来越多地被用于完善市场策略和优化药物开发过程，从而获得竞争优势。

主要趋势和驱动因素：

受胃肠道疾病发病率上升和全球人口老化趋势的推动，消化器官系统药物市场正经历强劲增长。关键趋势包括新型生物製剂和生物相似药的研发，这些药物提供标靶治疗，并具有更高的疗效和安全性。个人化医疗的进步也在重塑市场格局，使治疗方法能够根据患者的个别需求量身定制。肥胖和糖尿病等文明病的增加推动了对消化器官系统药物的需求。缓释製剂等药物传递系统的进步提高了病患的遵从性和治疗效果。此外，数位健康技术的整合正在革新病患管理，提供即时监测和个人化治疗方案。新兴市场拥有完善的医疗基础设施，并不断扩大先进疗法的覆盖范围，蕴藏着许多机会。投资研发以满足未被满足的医疗需求的公司，将更有利于掌握这些成长前景。对经济高效且易于获得的治疗方案的关注，也为市场扩张开闢了新的途径。在创新和不断发展的患者照护模式的驱动下，消化器官系统药物市场有望取得重大进展。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 制酸剂
    • 泻药
    • 止泻
    • 抗溃疡药物
    • 止吐药
    • 生物製药
    • 质子帮浦阻断剂
    • H2受体拮抗剂
  • 市场规模及预测：依产品划分
    • 药片
    • 胶囊
    • 粉末
    • 液体
    • 注射
    • 凝胶
    • 栓剂
    • 奶油
  • 市场规模及预测：依应用领域划分
    • 大肠激躁症
    • 胃食道逆流症
    • 消化性溃疡病
    • 克隆氏症
    • 溃疡性大肠炎
    • 乳糜泻
    • 憩室炎
    • 功能性消化不良
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 居家医疗环境
    • 专业医疗中心
    • 研究所
    • 诊断中心
    • 学术机构
    • 製药公司
  • 市场规模及预测：依技术划分
    • 生物技术
    • 合成
    • 奈米科技
    • 重组DNA
    • 高通量筛检
  • 市场规模及预测：依类型
    • 固态的
    • 液体
    • 半固态
  • 市场规模及预测：依组件划分
    • 原料药
    • 添加剂
    • 防腐剂
    • 着色剂
    • 吸附剂
    • 润滑剂
    • 涂层剂
  • 市场规模及预测：依製程划分
    • 配方
    • 製造业
    • 包装
    • 品管
    • 分配
  • 市场规模及预测：按模式
    • 处方药
    • 非处方药

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Ironwood Pharmaceuticals
  • Salix Pharmaceuticals
  • Almirall
  • Ferring Pharmaceuticals
  • Ardelyx
  • Red Hill Biopharma
  • Phathom Pharmaceuticals
  • Antibe Therapeutics
  • Innovate Biopharmaceuticals
  • Progenity
  • Synthetic Biologics
  • Genfit
  • Galectin Therapeutics
  • 9 Meters Biopharma
  • Trulance
  • Iterum Therapeutics
  • Assembly Biosciences
  • Adare Pharmaceuticals
  • Theravance Biopharma
  • Sterna Biologicals

第九章：关于我们

简介目录
Product Code: GIS31474

Gastrointestinal Drugs Market is anticipated to expand from $61.2 billion in 2024 to $101.4 billion by 2034, growing at a CAGR of approximately 5.3%. The Gastrointestinal Drugs Market encompasses pharmaceuticals designed to treat digestive system disorders, including acid-related diseases, constipation, and inflammatory bowel conditions. This market is driven by rising prevalence of gastrointestinal diseases, aging populations, and increasing awareness of gut health. Innovations in drug delivery systems and biologics are enhancing treatment efficacy and patient compliance, while emerging markets offer growth opportunities. The market is characterized by a competitive landscape with a focus on R&D and strategic collaborations to address unmet medical needs.

The Gastrointestinal Drugs Market is experiencing robust growth, propelled by rising incidences of gastrointestinal disorders and advancements in drug formulations. The acid neutralizers segment, particularly proton pump inhibitors, leads in performance due to their efficacy in treating acid-related conditions. Antiemetics, especially serotonin receptor antagonists, emerge as the second highest-performing sub-segment, driven by their effectiveness in managing nausea and vomiting. Biologics are gaining prominence, offering targeted therapies for chronic conditions like inflammatory bowel disease. The over-the-counter drugs segment is witnessing increased demand, reflecting consumer preference for accessible treatment options. Prescription drugs continue to dominate, with innovative therapies enhancing patient outcomes. The development of novel drug delivery systems, such as extended-release formulations, is enhancing therapeutic efficacy and patient compliance. Strategic collaborations and research investments are accelerating the introduction of advanced gastrointestinal drugs, further boosting market potential. The focus on personalized medicine is anticipated to transform treatment paradigms, offering significant growth opportunities.

Market Segmentation
TypeAntacids, Laxatives, Antidiarrheal, Antiulcerants, Antiemetics, Biologics, Proton Pump Inhibitors, H2 Receptor Antagonists
ProductTablets, Capsules, Powders, Liquids, Injectables, Gels, Suppositories, Creams
ApplicationIrritable Bowel Syndrome, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Crohn's Disease, Ulcerative Colitis, Celiac Disease, Diverticulitis, Functional Dyspepsia
End UserHospitals, Clinics, Homecare Settings, Specialty Centers, Research Institutes, Diagnostic Centers, Academic Institutions, Pharmaceutical Companies
TechnologyBiotechnology, Synthetic, Nanotechnology, Recombinant DNA, High-throughput Screening
FormSolid, Liquid, Semi-solid
ComponentActive Pharmaceutical Ingredients, Excipients, Preservatives, Colorants, Binders, Lubricants, Coatings
ProcessFormulation, Manufacturing, Packaging, Quality Control, Distribution
ModePrescription, Over-the-Counter

The Gastrointestinal Drugs Market is characterized by a diverse range of offerings, with established players maintaining significant market share through strategic pricing and innovative product launches. New entrants are making notable strides, particularly with novel formulations and targeted therapies that address unmet medical needs. The competitive landscape is dynamic, with companies leveraging advanced drug delivery systems to enhance efficacy and patient compliance. Pricing strategies remain competitive, reflecting the balance between accessibility and profitability. Emerging markets are witnessing increased penetration, driven by rising healthcare awareness and demand for effective gastrointestinal treatments. Competition benchmarking reveals a landscape dominated by a few key players, yet smaller firms are gaining traction through niche offerings. Regulatory influences are profound, with stringent approval processes shaping market entry and expansion. The FDA and EMA are pivotal in setting standards that affect drug lifecycle management. Market analysis indicates a trend toward personalized medicine, with biopharmaceutical advancements leading the charge. Data analytics and real-world evidence are increasingly utilized to refine market strategies and optimize drug development pathways, enhancing competitive positioning.

Geographical Overview:

The Gastrointestinal Drugs Market is witnessing varied growth across regions, each presenting unique opportunities. North America maintains a dominant position due to a high prevalence of gastrointestinal disorders and significant healthcare expenditure. The region's advanced healthcare infrastructure supports the swift adoption of novel therapies. Europe follows closely, driven by an aging population and increased awareness of gastrointestinal health. In Asia Pacific, the market is expanding rapidly. This growth is fueled by rising healthcare investments and increasing incidences of gastrointestinal diseases. Emerging economies like India and China are pivotal, with their large patient pools and improving healthcare access. Latin America is gradually becoming a significant player, with Brazil and Mexico leading the charge due to growing healthcare initiatives. The Middle East & Africa are also emerging as promising markets. Increased healthcare spending and a growing focus on improving healthcare infrastructure are key drivers. These regions are recognizing the importance of addressing gastrointestinal health to enhance overall population well-being.

Global tariffs and geopolitical dynamics are profoundly influencing the Gastrointestinal Drugs Market, especially in Japan, South Korea, China, and Taiwan. These nations are recalibrating strategies amid US-China trade tensions, with Japan and South Korea enhancing R&D investments to mitigate dependency on imports. China is advancing its pharmaceutical capabilities to counteract trade barriers, while Taiwan leverages its robust biotech sector despite geopolitical vulnerabilities. The parent market is witnessing steady growth driven by rising gastrointestinal disorders and an aging population. By 2035, the market is expected to evolve with increased regional collaboration and innovation in drug formulations. Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy prices, indirectly impacting production costs and market dynamics in the pharmaceutical sector.

Key Trends and Drivers:

The gastrointestinal drugs market is experiencing robust growth, fueled by rising incidences of gastrointestinal disorders and an aging global population. Key trends include the development of novel biologics and biosimilars, which offer targeted therapies with improved efficacy and safety profiles. The advent of personalized medicine is also shaping the market, with treatments increasingly tailored to individual patient needs. The increasing prevalence of lifestyle-related conditions such as obesity and diabetes is driving demand for gastrointestinal drugs. Advances in drug delivery systems, such as extended-release formulations, are enhancing patient compliance and treatment outcomes. Furthermore, the integration of digital health technologies is revolutionizing patient management, providing real-time monitoring and personalized treatment plans. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced therapies is expanding. Companies investing in research and development to address unmet medical needs are well-positioned to capitalize on these growth prospects. The focus on cost-effective and accessible treatment options is also opening new avenues for market expansion. The gastrointestinal drugs market is poised for significant advancements, driven by innovation and evolving patient care paradigms.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antacids
    • 4.1.2 Laxatives
    • 4.1.3 Antidiarrheal
    • 4.1.4 Antiulcerants
    • 4.1.5 Antiemetics
    • 4.1.6 Biologics
    • 4.1.7 Proton Pump Inhibitors
    • 4.1.8 H2 Receptor Antagonists
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Tablets
    • 4.2.2 Capsules
    • 4.2.3 Powders
    • 4.2.4 Liquids
    • 4.2.5 Injectables
    • 4.2.6 Gels
    • 4.2.7 Suppositories
    • 4.2.8 Creams
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Irritable Bowel Syndrome
    • 4.3.2 Gastroesophageal Reflux Disease
    • 4.3.3 Peptic Ulcer Disease
    • 4.3.4 Crohn's Disease
    • 4.3.5 Ulcerative Colitis
    • 4.3.6 Celiac Disease
    • 4.3.7 Diverticulitis
    • 4.3.8 Functional Dyspepsia
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Specialty Centers
    • 4.4.5 Research Institutes
    • 4.4.6 Diagnostic Centers
    • 4.4.7 Academic Institutions
    • 4.4.8 Pharmaceutical Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Synthetic
    • 4.5.3 Nanotechnology
    • 4.5.4 Recombinant DNA
    • 4.5.5 High-throughput Screening
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Solid
    • 4.6.2 Liquid
    • 4.6.3 Semi-solid
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Active Pharmaceutical Ingredients
    • 4.7.2 Excipients
    • 4.7.3 Preservatives
    • 4.7.4 Colorants
    • 4.7.5 Binders
    • 4.7.6 Lubricants
    • 4.7.7 Coatings
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Formulation
    • 4.8.2 Manufacturing
    • 4.8.3 Packaging
    • 4.8.4 Quality Control
    • 4.8.5 Distribution
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Prescription
    • 4.9.2 Over-the-Counter

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Form
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Form
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Form
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Form
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Form
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Form
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Form
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Form
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Form
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Form
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Form
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Form
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Form
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Form
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Form
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Form
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Form
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Form
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Form
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Form
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Form
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Form
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Form
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Form
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Ironwood Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Salix Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Almirall
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Ferring Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ardelyx
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Red Hill Biopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Phathom Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Antibe Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Innovate Biopharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Progenity
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Synthetic Biologics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genfit
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Galectin Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 9 Meters Biopharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Trulance
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Iterum Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Assembly Biosciences
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Adare Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Theravance Biopharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Sterna Biologicals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us